Deepak L. Bhatt

Last updated
Deepak L. Bhatt
CitizenshipUnited States
Alma materMassachusetts Institute of Technology, Cornell University, Harvard University, University of Oxford
Known forCardiovascular medicine, interventional cardiology
Scientific career
FieldsClinical investigator, educator, author, cardiology
InstitutionsCleveland Clinic, VA Medical Center, Brigham and Women's Hospital, Harvard Medical School, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai
Website https://deepakbhattmd.com/

Deepak L. Bhatt is a US interventional cardiologist, researcher, and educator. He is known for novel clinical trials in cardiovascular prevention, intervention, and heart failure. As of 2024, he is the director of Mount Sinai Fuster Heart Hospital in New York City and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System. [1] [2] Prior, he served as the executive director of Interventional Cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center and a professor of medicine at Harvard Medical School. [3] [4] He was given the American College of Cardiology's Distinguished Mentor Award in 2018, and in 2019, the American Heart Association presented him with its Distinguished Scientist award. [5] As of 2024, Google Scholar reports that he has been cited 279,202 times, has an h-index of 194, and an i10-index of 1,249.

Contents

Education and career

Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. [6] He received his Executive MBA from the University of Oxford in 2024. [7]

He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic [8] where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center. [9]

Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women’s Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. [8] In 2012, he was appointed a professor of medicine at Harvard Medical School. [10]

Board positions

As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb. [11] He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology. [7] He serves on the Board of Directors of the American Heart Association New York City chapter. [12]

Research

Focus

Bhatt focuses on several areas of cardiology, including interventional cardiology, heart attacks, stroke, prevention, and heart failure, as well as related areas such as high cholesterol, diabetes, and obesity. [13] AD Scientific Index ranks him as one of the top 3% of scientists worldwide in his field. [14]

Recent trials

Recent trials as of 2024 include:

Name, sponsor, roleDescription
SOLOIST, Sanofi Lexicon, Chair [15] Randomized controlled clinical trial (RCT) of sotagliflozin versus placebo in patients with diabetes and acute decompensated heart failure.
SCORED, Sanofi Lexicon, Chair [16] RCT of sotagliflozin versus placebo in patients with diabetes and at high cardiovascular risk.
REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial), Amarin, Chair and PI. [17] To determine definitively whether icosapent ethyl does or does not reduce cardiovascular risk in patients receiving intensive statin therapy.
CHAMPION PHOENIX, Chiesi, Co-Chair and Co-PI [18] Industry-sponsored Phase 3 trial of cangrelor versus placebo in 11,000 patients undergoing percutaneous coronary intervention.
THEMIS, AstraZeneca, Co-Chair and Co-PI [19] This is an international, multicenter, randomized trial of patients with diabetes and stable coronary artery disease randomized to the oral antiplatelet ticagrelor or to placebo on top of standard of care including aspirin.

Honors and awards

Brigham and Women’s Hospital chose Bhatt in 2014 as the Eugene Braunwald Scholar and in 2016 presented him with the Research Mentor Award, and in 2017 he was awarded the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology. [6] He was given the American College of Cardiology’s Distinguished Mentor Award in 2018, [20] and in 2019, the American Heart Association’s Distinguished Scientist Award. [5] [21] He received NLA’s Honorary Lifetime Membership Award in 2021, and the Society for Cardiovascular Angiography and Interventions’ Master Designation in 2022. [2] Also in 2022, Research.com recognized him with its Best Scientists award. [13]

Publications

Books and book chapters

Bhatt is the Editor of the first and second editions of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease [22] and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. [23] He is one of the co-editors of Braunwald’s Heart Disease. [24] Elsevier credits him with a total of 11 titles as an author, chapter contributor, and editor. [25]

Editorial

Bhatt was Senior Associate Editor for News and Clinical Trials for ACC.org, member of the Healio | Cardiology Today Editorial Board, [26] and Editor-in-Chief of the Journal of Invasive Cardiology, which also lists him as: [27]

Articles

As of 2024, Google Scholar reports that he has been cited 279,202 times, has an h-index of 194 and an i10-index of 1,249. [31]

Bhatt has authored or co-authored over 2,000 publications [32] and has been listed by the Web of Science Group as a highly cited researcher from 2014 to 2023. [33] [34] [35]

Bhatt's most cited, peer-reviewed articles include:

Related Research Articles

<span class="mw-page-title-main">Cardiology</span> Branch of medicine dealing with the heart

Cardiology is the study of the heart. Cardiology is a branch of medicine that deals with disorders of the heart and the cardiovascular system. The field includes medical diagnosis and treatment of congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology. Physicians who specialize in this field of medicine are called cardiologists, a specialty of internal medicine. Pediatric cardiologists are pediatricians who specialize in cardiology. Physicians who specialize in cardiac surgery are called cardiothoracic surgeons or cardiac surgeons, a specialty of general surgery.

<span class="mw-page-title-main">Coronary artery disease</span> Reduction of blood flow to the heart

Coronary artery disease (CAD), also called coronary heart disease (CHD), ischemic heart disease (IHD), myocardial ischemia, or simply heart disease, involves the reduction of blood flow to the cardiac muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. Types include stable angina, unstable angina, and myocardial infarction.

<span class="mw-page-title-main">Cardiovascular disease</span> Class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

<span class="mw-page-title-main">Hypercholesterolemia</span> High levels of cholesterol in the blood

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, hyperlipoproteinemia, and dyslipidemia.

Dyslipidemia is a metabolic disorder characterized by abnormally high or low amounts of any or all lipids or lipoproteins in the blood. Dyslipidemia is a risk factor for the development of atherosclerotic cardiovascular diseases (ASCVD), which include coronary artery disease, cerebrovascular disease, and peripheral artery disease. Although dyslipidemia is a risk factor for ASCVD, abnormal levels don't mean that lipid lowering agents need to be started. Other factors, such as comorbid conditions and lifestyle in addition to dyslipidemia, is considered in a cardiovascular risk assessment. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin resistance can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

<span class="mw-page-title-main">Atorvastatin</span> Cholesterol-lowering medication

Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Acute coronary syndrome</span> Medical condition

Acute coronary syndrome (ACS) is a syndrome due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is centrally located pressure-like chest pain, often radiating to the left shoulder or angle of the jaw, and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly women, older people, and people with diabetes mellitus.

<span class="mw-page-title-main">Percutaneous coronary intervention</span> Medical techniques used to manage coronary occlusion

Percutaneous coronary intervention (PCI) is a minimally invasive non-surgical procedure used to treat narrowing of the coronary arteries of the heart found in coronary artery disease. The procedure is used to place and deploy coronary stents, a permanent wire-meshed tube, to open narrowed coronary arteries. PCI is considered 'non-surgical' as it uses a small hole in a peripheral artery (leg/arm) to gain access to the arterial system, an equivalent surgical procedure would involve the opening of the chest wall to gain access to the heart area. The term 'coronary angioplasty with stent' is synonymous with PCI. The procedure visualises the blood vessels via fluoroscopic imaging and contrast dyes. PCI is performed by an interventional cardiologists in a catheterization laboratory setting.

<span class="mw-page-title-main">Paul Ridker</span> American epidemiologist and academic

Paul M. Ridker is a cardiovascular epidemiologist and biomedical researcher. He is currently the Eugene Braunwald Professor of Medicine at Harvard University and Brigham and Women's Hospital, where he directs the Center for Cardiovascular Disease Prevention. Ridker also holds an appointment as Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

<span class="mw-page-title-main">Saxagliptin</span> Chemical compound

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.

The history of invasive and interventional cardiology is complex, with multiple groups working independently on similar technologies. Invasive and interventional cardiology is currently closely associated with cardiologists, though the development and most of its early research and procedures were performed by diagnostic and interventional radiologists.

<span class="mw-page-title-main">Valentín Fuster</span> Spanish cardiologist

Valentín Fuster Carulla, 1st Marquess of Fuster is a Spanish cardiologist and aristocrat.

<span class="mw-page-title-main">Ticagrelor</span> Coronary medication

Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca.

<span class="mw-page-title-main">Myocardial infarction</span> Interruption of cardiac blood supply

A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn.

<span class="mw-page-title-main">Complications of hypertension</span>

Complications of hypertension are clinical outcomes that result from persistent elevation of blood pressure. Hypertension is a risk factor for all clinical manifestations of atherosclerosis since it is a risk factor for atherosclerosis itself. It is an independent predisposing factor for heart failure, coronary artery disease, stroke, kidney disease, and peripheral arterial disease. It is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries.

Jean-Claude Tardif is the Director of the Research Center at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. He received his medical degree (MD) in 1987 from the University of Montreal and specialized in cardiology and research in Montreal and Boston until 1994. Dr. Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is also the Scientific Director of the Montreal Health Innovations Coordinating Center (MHICC).

Professor Aly Saad, is a professor of cardiology at Zagazig University and a member of the higher committee of promotion of professors and assistant professors of cardiovascular diseases and critical care subspecialty in Egypt.

Major adverse cardiovascular events is a composite endpoint frequently used in cardiovascular research. Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which makes comparison of similar studies difficult.

<span class="mw-page-title-main">Roxana Mehran</span> Cardiologist

Roxana Mehran is an Iranian-American cardiologist and Mount Sinai Endowed Professor of Medicine at the Icahn School of Medicine at Mount Sinai. She is known for her work in interventional cardiology.

<span class="mw-page-title-main">Roberto Ferrari (cardiologist)</span> Italian Cardiologist

Roberto Ferrari is an Italian cardiologist who holds the position of Emeritus Professor at the University of Ferrara, where besides he was the chair of the Cardiology in the School of Medicine until the 2019–2020 academic year.

References

  1. ↑ "Deepak L. Bhatt - Interventional Cardiology | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2023-11-11.
  2. 1 2 "ORCID". orcid.org. Retrieved 2023-11-12.
  3. ↑ "Transformative Teachers presents an interview with Dr. Deepak Bhatt | Innovative Therapeutics" . Retrieved 2023-11-11.
  4. ↑ MA, John Schieszer (2015-11-12). "Gender Disparities Exist in Cardiovascular Care". Endocrinology Advisor. Retrieved 2024-02-17.
  5. 1 2 "2019 Distinguished Scientist - Deepak L. Bhatt, MD, MPH, FAHA". professional.heart.org. Retrieved 2023-11-13.
  6. 1 2 "Deepak Bhatt, MD, MPH, FAHA". www.heart.org. Retrieved 2023-11-11.
  7. 1 2 "Deepak Bhatt". PracticeUpdate. Retrieved 2023-11-13.
  8. 1 2 3 "Harvard Health". www.health.harvard.edu. Retrieved 2023-11-12.
  9. ↑ "Deepak L. Bhatt, MD, MPH, MSCAI | SCAI". scai.org. Retrieved 2023-11-12.
  10. ↑ "Deepak Bhatt, MD, MPH - University Hospitals". cme.uhhospitals.org. Retrieved 2023-11-12.
  11. ↑ "Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors". investingnews.com. Retrieved 2023-11-13.
  12. ↑ "Deepak L. Bhatt, MD, MPH, FACC". American College of Cardiology. Retrieved 2024-03-13.
  13. 1 2 "Deepak L. Bhatt Profile". Research.com. Retrieved 2023-09-12.
  14. ↑ Index, AD Scientific. "Deepak L. Bhatt - AD Scientific Index 2024". www.adscientificindex.com. Retrieved 2023-11-12.
  15. ↑ Bhatt, Deepak L.; Szarek, Michael; Steg, P. Gabriel; Cannon, Christopher P.; Leiter, Lawrence A.; McGuire, Darren K.; Lewis, Julia B.; Riddle, Matthew C.; Voors, Adriaan A.; Metra, Marco; Lund, Lars H.; Komajda, Michel; Testani, Jeffrey M.; Wilcox, Christopher S.; Ponikowski, Piotr (2021-01-14). "Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure". The New England Journal of Medicine. 384 (2): 117–128. doi:10.1056/NEJMoa2030183. ISSN   1533-4406. PMID   33200892.
  16. ↑ Bhatt, Deepak L.; Szarek, Michael; Pitt, Bertram; Cannon, Christopher P.; Leiter, Lawrence A.; McGuire, Darren K.; Lewis, Julia B.; Riddle, Matthew C.; Inzucchi, Silvio E.; Kosiborod, Mikhail N.; Cherney, David Z. I.; Dwyer, Jamie P.; Scirica, Benjamin M.; Bailey, Clifford J.; Díaz, Rafael (2021-01-14). "Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease". The New England Journal of Medicine. 384 (2): 129–139. doi:10.1056/NEJMoa2030186. ISSN   1533-4406. PMID   33200891.
  17. ↑ Bhatt, Deepak L.; Steg, P. Gabriel; Miller, Michael; Brinton, Eliot A.; Jacobson, Terry A.; Ketchum, Steven B.; Doyle, Ralph T.; Juliano, Rebecca A.; Jiao, Lixia; Granowitz, Craig; Tardif, Jean-Claude; Ballantyne, Christie M.; REDUCE-IT Investigators (2019-01-03). "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia". The New England Journal of Medicine. 380 (1): 11–22. doi:10.1056/NEJMoa1812792. ISSN   1533-4406. PMID   30415628.
  18. ↑ Bhatt, Deepak L.; Stone, Gregg W.; Mahaffey, Kenneth W.; Gibson, C. Michael; Steg, P. Gabriel; Hamm, Christian W.; Price, Matthew J.; Leonardi, Sergio; Gallup, Dianne; Bramucci, Ezio; Radke, Peter W.; Widimský, Petr; Tousek, Frantisek; Tauth, Jeffrey; Spriggs, Douglas (2013-04-04). "Effect of platelet inhibition with cangrelor during PCI on ischemic events". The New England Journal of Medicine. 368 (14): 1303–1313. doi:10.1056/NEJMoa1300815. ISSN   1533-4406. PMID   23473369.
  19. ↑ Clavijo, Leonardo C.; Maya, Juan; Carlson, Glenn; Angiolillo, Dominick J.; Teng, Renli; Caplan, Richard; Price, Matthew J. "Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus". Cardiovascular Revascularization Medicine: Including Molecular Interventions. 16 (8): 450–454. doi: 10.1016/j.carrev.2015.08.007 . ISSN   1878-0938. PMID   26440227.
  20. ↑ "2019 Distinguished Scientist - Deepak L. Bhatt, MD, MPH, FAHA". professional.heart.org. Retrieved 2023-11-11.
  21. ↑ "Physician Spotlight: Oakstone Course Director, Dr. Deepak Bhatt, Named 'Distinguished Scientist'". Oakstone | CME. Retrieved 2023-11-12.
  22. ↑ "Scientific publications and co-authored articles, 2008". dx.doi.org. Retrieved 2023-11-12.
  23. ↑ Bhatt, Deepak (December 17, 2020). Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease: Expert Consult. Elsevier. ISBN   0323673619.
  24. ↑ Bhatt, Deepak. Braunwald’s Heart Disease. Elsevier. ISBN   0323722199.
  25. ↑ "Search results for: 'Deepak L. Bhatt'". www.asia.elsevierhealth.com. Retrieved 2023-11-12.
  26. ↑ "VIDEO: Deepak L. Bhatt, MD, MPH, highlights new data on semaglutide, tirzepatide at AHA". www.healio.com. Retrieved 2024-02-10.
  27. ↑ "Journal of Invasive Cardiology". www.hmpgloballearningnetwork.com. Retrieved 2023-11-12.
  28. ↑ "Dr. Deepak L. Bhatt named Editor-in-Chief of the Journal of Invasive Cardiology". www.hmpgloballearningnetwork.com. Retrieved 2023-11-13.
  29. ↑ "Bhatt, Deepak L." Pri-Med. Retrieved 2023-11-13.
  30. ↑ "Call for Trial Designs, Outcomes Research and Clinical Trial Updates". Clinical Cardiology. Retrieved 2023-09-12.
  31. ↑ "Deepak L. Bhatt, MD, MPH". scholar.google.com. Retrieved 2023-11-12.
  32. ↑ "High Enroll Welcomes Dr. Deepak L. Bhatt, MD, MPH as our Newest Board Member". High Enroll. Retrieved 2023-09-12.
  33. ↑ "CMHC Faculty Members". Cardiometabolic Health Congress. Retrieved 2023-09-12.
  34. ↑ "Bhatt DL - Search Results - PubMed". PubMed. Retrieved 2024-02-09.
  35. ↑ Communication, Brigham Office of Strategic (2021-11-16). "Thirty Brigham Researchers Named to Clarivate's 2021 Highly Cited Researchers List". Brigham Clinical & Research News. Retrieved 2024-02-09.
  36. ↑ Wiviott, Stephen D.; Raz, Itamar; Bonaca, Marc P.; Mosenzon, Ofri; Kato, Eri T.; Cahn, Avivit; Silverman, Michael G.; Zelniker, Thomas A.; Kuder, Julia F.; Murphy, Sabina A. (2019). "Dapagliflozin and cardiovascular outcomes in type 2 diabetes". New England Journal of Medicine. 380 (4): 347–357.
  37. ↑ Scirica, Benjamin M.; Bhatt, Deepak L.; Braunwald, Eugene; Steg, P. Gabriel; Davidson, Jaime; Hirshberg, Boaz; Ohman, Peter; Frederich, Robert; Wiviott, Stephen D.; Hoffman, Elaine B. (2013). "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus". New England Journal of Medicine. 369 (14): 1317–1326.
  38. ↑ Scirica, Benjamin M.; Bhatt, Deepak L.; Braunwald, Eugene; Steg, P. Gabriel; Davidson, Jaime; Hirshberg, Boaz; Ohman, Peter; Frederich, Robert; Wiviott, Stephen D.; Hoffman, Elaine B.; Cavender, Matthew A.; Udell, Jacob A.; Desai, Nihar R.; Mosenzon, Ofri; McGuire, Darren K. (2013-10-03). "Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus". New England Journal of Medicine. 369 (14): 1317–1326. doi:10.1056/NEJMoa1307684. hdl: 10072/67407 . ISSN   0028-4793.
  39. ↑ "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus". scholar.google.com. Retrieved 2024-02-10.
  40. ↑ Adams Jr, Harold P.; Del Zoppo, Gregory; Alberts, Mark J.; Bhatt, Deepak L.; Brass, Lawrence; Furlan, Anthony; Grubb, Robert L.; Higashida, Randall T.; Jauch, Edward C.; Kidwell, Chelsea (2007). "Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists". Stroke. 38 (5): 1655–1711.
  41. ↑ Adams, Harold P.; del Zoppo, Gregory; Alberts, Mark J.; Bhatt, Deepak L.; Brass, Lawrence; Furlan, Anthony; Grubb, Robert L.; Higashida, Randall T.; Jauch, Edward C.; Kidwell, Chelsea; Lyden, Patrick D.; Morgenstern, Lewis B.; Qureshi, Adnan I.; Rosenwasser, Robert H.; Scott, Phillip A. "Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists". Stroke. 38 (5): 1655–1711. doi:10.1161/STROKEAHA.107.181486. ISSN   0039-2499.
  42. ↑ Mehran, Roxana; Rao, Sunil V.; Bhatt, Deepak L.; Gibson, C. Michael; Caixeta, Adriano; Eikelboom, John; Kaul, Sanjay; Wiviott, Stephen D.; Menon, Venu; Nikolsky, Eugenia (2011). "Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium". Circulation. 123 (23): 2736–2747.
  43. ↑ Bhatt, Deepak L.; Fox, Keith A.A.; Hacke, Werner; Berger, Peter B.; Black, Henry R.; Boden, William E.; Cacoub, Patrice; Cohen, Eric A.; Creager, Mark A.; Easton, J. Donald; Flather, Marcus D.; Haffner, Steven M.; Hamm, Christian W.; Hankey, Graeme J.; Johnston, S. Claiborne (2006-04-20). "Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events". New England Journal of Medicine. 354 (16): 1706–1717. doi:10.1056/NEJMoa060989. ISSN   0028-4793.
  44. ↑ Bhatt, Deepak L.; Fox, Keith AA; Hacke, Werner; Berger, Peter B.; Black, Henry R.; Boden, William E.; Cacoub, Patrice; Cohen, Eric A.; Creager, Mark A.; Easton, J. Donald (2006). "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events". New England Journal of Medicine. 354 (16): 1706–1717.
  45. ↑ Bhatt, Deepak L.; Steg, P. Gabriel; Miller, Michael; Brinton, Eliot A.; Jacobson, Terry A.; Ketchum, Steven B.; Doyle, Ralph T.; Juliano, Rebecca A.; Jiao, Lixia; Granowitz, Craig; Tardif, Jean-Claude; Ballantyne, Christie M. (2019-01-03). "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia". New England Journal of Medicine. 380 (1): 11–22. doi:10.1056/NEJMoa1812792. ISSN   0028-4793.
  46. ↑ Bhatt, Deepak L.; Kandzari, David E.; O'Neill, William W.; D'Agostino, Ralph; Flack, John M.; Katzen, Barry T.; Leon, Martin B.; Liu, Minglei; Mauri, Laura; Negoita, Manuela; Cohen, Sidney A.; Oparil, Suzanne; Rocha-Singh, Krishna; Townsend, Raymond R.; Bakris, George L. (2014-04-10). "A Controlled Trial of Renal Denervation for Resistant Hypertension". New England Journal of Medicine. 370 (15): 1393–1401. doi:10.1056/NEJMoa1402670. ISSN   0028-4793.
  47. ↑ Bhatt, Deepak L.; Szarek, Michael; Steg, P. Gabriel; Cannon, Christopher P.; Leiter, Lawrence A.; McGuire, Darren K.; Lewis, Julia B.; Riddle, Matthew C.; Voors, Adriaan A.; Metra, Marco; Lund, Lars H.; Komajda, Michel; Testani, Jeffrey M.; Wilcox, Christopher S.; Ponikowski, Piotr (2021-01-14). "Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure". New England Journal of Medicine. 384 (2): 117–128. doi:10.1056/NEJMoa2030183. ISSN   0028-4793.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.